ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Premium IconPremium Help Menu
CAC 40
7 502,78
0,27%
Dow Jones
40 093,40
1,23%
DAX
22 064,51
0,60%
Brent Oil
65,94
0,26%
Bitcoin
93 790,46
-0,19%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) Actualités

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RARE
DateHeureSourceTitreSymboleSociété
24/04/202515h12Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RAREUltragenyx Pharmaceutical Inc
22/04/202523h00GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
28/03/202522h02Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:RAREUltragenyx Pharmaceutical Inc
28/03/202522h01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RAREUltragenyx Pharmaceutical Inc
28/03/202522h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/03/202517h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
27/02/202523h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
24/02/202522h30GlobeNewswire Inc.Ultragenyx to Participate at Investor Conferences in MarchNASDAQ:RAREUltragenyx Pharmaceutical Inc
19/02/202522h58Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAREUltragenyx Pharmaceutical Inc
18/02/202514h00GlobeNewswire Inc.Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
13/02/202522h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
13/02/202522h01GlobeNewswire Inc.Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/02/202522h30GlobeNewswire Inc.Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
05/02/202514h00GlobeNewswire Inc.Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained ReductionNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/01/202517h00GlobeNewswire Inc.Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 MilestonesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/01/202522h30GlobeNewswire Inc.Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
19/12/202422h05GlobeNewswire Inc.Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
19/12/202414h00GlobeNewswire Inc.Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
26/11/202422h30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in DecemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
09/11/202416h30GlobeNewswire Inc.Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitNASDAQ:RAREUltragenyx Pharmaceutical Inc
05/11/202422h01GlobeNewswire Inc.Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
29/10/202421h05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/10/202414h00GlobeNewswire Inc.Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis ImperfectaNASDAQ:RAREUltragenyx Pharmaceutical Inc
03/10/202422h30GlobeNewswire Inc.Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
26/09/202414h00GlobeNewswire Inc.Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
29/08/202422h30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in SeptemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
23/08/202413h00Business WireTactical Resources, a Growing North American Rare Earth Elements Company, to List on NASDAQNASDAQ:RAREUltragenyx Pharmaceutical Inc
01/08/202422h05GlobeNewswire Inc.Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
25/07/202422h05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
24/07/202414h00GlobeNewswire Inc.Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumNASDAQ:RAREUltragenyx Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:RARE

Dernières Valeurs Consultées

LSE
40GJ
Bank Ire.nts25
CSE
LOOP
Good Flour
BOV
BPAC3Q
BTG PACTUAL ON
USOTC
GUBRF
Gubra AS (PK)
NASDAQ
HUGH
BIT
P1KV03
BNP Paribas Issuance
AMEX
SMTH
Alps
BIT
UC5F0L
Unicredit Bank
LSE
TANN
Solarenergyacc
BIT
W1WCX6
UBS
BIT
UB4QEN
Unicredit Bank
HITB
MIPSBTC
MIPSToken
NASDAQ
WEB
Web.com Group, Inc.
AMEX
EEI
Ecology Environment
NYSE
OSH
Oak Street Health
LSE
0QMS
Dormakaba
Delayed Upgrade Clock
ADVFN Logo
France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces